Halozyme Therapeutics (HALO) reported Q4 non-GAAP earnings Tuesday of $1.26 per diluted share, up from $0.82 a year earlier.
Analysts polled by FactSet expected $1.13
Revenue in the three months ended Dec. 31 rose to $298 million from $230 million a year earlier.
Analysts surveyed by FactSet expected $285.7 million.
The company reiterated 2025 non-GAAP diluted EPS guidance of $4.95 to $5.35 on revenue of $1.15 billion to $1.23 billion.
Analysts polled by FactSet expect EPS of $4.90 on revenue of $1.19 billion.
Shares of the company rose 1.9% in after-hours trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。